Traverse Biotech to Present Data on ROR2-Targeted T-Cell Engager at the Society for Immunotherapy of Cancer’s (SITC) 39th Annual Meeting

On October 25, 2024 Traverse Biotech, Inc., a privately held biotechnology company specializing in innovative immunotherapy solutions, reported that it will present a poster at the Society for Immunotherapy of Cancer (SITC) (Free SITC Whitepaper)’s (SITC) (Free SITC Whitepaper) 39th Annual Meeting, taking place November 6-10, 2024, in Houston, TX (Press release, Traverse Biotech, OCT 25, 2024, View Source [SID1234647431]). The presentation will showcase preclinical results on TB-Bs1, Traverse’s T-cell engaging product candidate targeting ROR2-positive solid tumors.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Poster Presentation Details:

Title: ROR2-targeted T-cell engager as a novel therapeutic approach in solid tumors
Abstract Number: 1065
Location: Exhibit Halls A-B, George R. Brown Convention Center
Date: Friday, November 8, 2024
Attending from Traverse Biotech:

Brandy Houser, Ph.D., Co-Founder & Chief Executive Officer
Jing Gong, Ph.D., Director of Strategy and Operations
About TB-Bs1
TB-Bs1 is a first-in-class T-cell Engaging (TCE) bispecific antibody built on the DuoBody platform targeting ROR2. ROR2 is a receptor that has been shown to cause cancer cell proliferation and that has also been identified as a negative prognostic indicator. ROR2 is a member of the receptor tyrosine kinase-like orphan receptor family associated with Wnt signaling. We and others have confirmed ROR2 protein expression in liquid and solid cancers, with TB-Bs1 demonstrating consistent cytotoxic activity against ROR2-positive cancer cell lines. In a humanized mouse model, TB-Bs1 significantly inhibited tumor growth in a dose-dependent manner with minimal adverse effects. These results highlight the potential of TB-Bs1 as a targeted immunotherapy for ROR2-positive cancers.

enGene Announces $60 Million Private Placement Financing

On October 25, 2024 enGene Holdings Inc. (Nasdaq: ENGN or "enGene" or the "Company"), a clinical-stage genetic medicines company whose non-viral lead investigational product detalimogene voraplasmid (also known as detalimogene, and previously EG-70) is in an ongoing pivotal study in patients with high-risk, Bacillus Calmette-Guérin (BCG)-unresponsive, non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ (Cis), reported that it has agreed to sell 6,758,311 of its common shares at a price per share of $8.90 (Press release, enGene, OCT 25, 2024, View Source [SID1234647433]). The financing is expected to close on October 29, 2024, subject to customary closing conditions. enGene anticipates the gross proceeds from the private placement to be approximately $60 million, before deducting any offering-related expenses.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The financing included participation from new and existing investors, including Deep Track Capital, Cormorant Asset Management, Forbion, OrbiMed, Sphera Healthcare, Vestal Point Capital and Venrock Healthcare Capital Partners.

enGene intends to use the net proceeds from this financing to fund the continued development of detalimogene, pre-commercial activities, the potential expansion of the DDX platform, and for working capital and general corporate purposes. The proceeds from this financing, combined with current cash and cash equivalents, are expected to be sufficient to fund the current operating plan into 2027.

Leerink Partners, Piper Sandler & Co., Guggenheim Securities and Wells Fargo Securities are acting as placement agents to the Company in connection with the private placement.

The securities described above have not been registered under the Securities Act of 1933, as amended. Accordingly, these securities may not be offered or sold in the United States, except pursuant to an effective registration statement or an applicable exemption from the registration requirements of the Securities Act. enGene has agreed to file a registration statement with the U.S. Securities and Exchange Commission (the "SEC") registering the resale of the common shares issued in this private placement. Any offering of the securities under the resale registration statement will only be made by means of a prospectus.

This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such jurisdiction.

Egle Therapeutics to Share Preclinical Efficacy Data for EGL-001, a CTLA-4/CD25 Antagonist Fusion Protein at the Society for Immunotherapy of Cancer Meeting

On October 25, 2024 Egle Therapeutics, a biotechnology company focused on advancing the next generation of regulatory T cell-focused therapies for oncology and auto-immunity, reported that it will present at the Society for Immunotherapy of Cancer (SITC) (Free SITC Whitepaper) Meeting taking place in Houston, Texas from November 6th to 10th, 2024 (Press release, Egle Therapeutics, OCT 25, 2024, View Source [SID1234647434]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The presentation, entitled "Preferential tumor retention of EGL-001, a CTLA-4/CD25 antagonist fusion protein, to selectively deplete tumor Tregs and minimize peripheral toxicities: towards a first-in-human clinical study", will highlight the development and promising preclinical results of EGL-001, a humanized antibody designed to selectively target regulatory T cells (Tregs) within the tumor microenvironment. The data showcases EGL-001’s potential as single-agent and to enhance the effectiveness of immune checkpoint blockade therapies by depleting tumor-associated Tregs, leading to increased CD8+ T cell activation and anti-tumor responses in preclinical models.

The SITC (Free SITC Whitepaper) presentation will include key findings from studies in mouse models and cynomolgus monkeys, demonstrating the safety, tolerability, and efficacy of EGL-001, as well as its preferential tumor accumulation and rapid clearance from peripheral organs. These promising results leading Egle Therapeutics to conduct a first-in-human open-label, phase I/II trial evaluating the safety, tolerability, PK and preliminary activity of EGL-001 in patients with selected solid tumors, with the goal to address the critical need for more effective immunotherapies in cancer treatment.

Session Date Saturday, Nov. 9 ; Location: George R. Brown Convention Center – Level 1 – Exhibit Halls AB ; Poster Board Number: 674

Alterome Therapeutics to Present Preclinical Data for its KRAS Selective Inhibitor ALTA3263 at the 2024 ENA Symposium

On October 25, 2024 Alterome Therapeutics, Inc., a biopharmaceutical company pioneering the development of next generation, small molecule targeted therapies for the treatment of cancer, reported that data from preclinical studies of ALTA3263, the Company’s potential best-in-class KRAS selective inhibitor, will be presented in a plenary oral session at the EORTC-NCI-AACR (Free EORTC-NCI-AACR Whitepaper) (ENA) Symposium, taking place on October 23-25 in Barcelona, Spain (Press release, Alterome Therapeutics, OCT 25, 2024, View Source [SID1234647435]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"ALTA3263 induces deep and durable tumor regressions in preclinical models addicted to the most common KRAS mutations, G12D, G12V, and G12C," said Eric Murphy, Ph.D., co-founder and CEO of Alterome Therapeutics. "Mutant KRAS is a driver in approximately 1 out of every 5 cancers and ALTA3263 has the potential to be a robust treatment option for a wide range of KRAS mutant cancers based on its compelling preclinical profile."

Key Findings:

ALTA3263 is an oral, KRAS selective inhibitor designed to enable complete target coverage of the most common mutations including G12V and G12D.
ALTA3263 demonstrates potent KRAS ON-state inhibition, picomolar to low single digit nanomolar potency against cells harboring a diverse array of KRAS driver mutations, and is highly selective for KRAS versus the NRAS and HRAS isoforms.
ALTA3263 induced complete and sustained tumor regressions in 8 KRAS G12V/D/C/A mutant xenograft models, including complete responses in 2 patient-derived xenograft non-small cell lung cancer models, while being well-tolerated during prolonged daily oral dosing in mice.
Oral Presentation Details:

Title: ALTA3263: an oral, KRAS isoform-selective, dual ON/OFF state, non-covalent inhibitor induces regressions across KRAS G12V, G12D, and G12C cancer models
Session Title: Proffered Papers: New drugs on the Horizon
Session Type: Plenary Session 6
Date and Time: Friday, October 25 at 12:36-12:48 p.m. CEST
Speaker/Lead Author: Tim Sen Wang, Ph.D., Alterome Therapeutics

Chugai Announces 2024 3rd Quarter Results

On October 25, 2024 Chugai Pharmaceutical Co., Ltd. (TOKYO: 4519) reported its financial results for the third quarter of fiscal year 2024 (Press release, Chugai, OCT 25, 2024, View Source [SID1234647417]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"In the third quarter of 2024, we achieved increased revenue and profit, primarily driven by strong overseas exports. While the domestic sales continued to be affected by the completion of government supply of Ronapreve in the previous year, as well as the impact of biosimilars and NHI drug price revisions, our overseas revenue growth was led by a significant increase in exports of our in-house developed product Hemlibra to Roche. In consideration of the good progress as of the third quarter, we raised our full year forecasts for FY2024. In research and development, PiaSky received approval in Europe for paroxysmal nocturnal hemoglobinuria (PNH), while NEMLUVIO(nemolizumab), out-licensed to Galderma, was approved in the United States for prurigo nodularis. Furthermore, Alecensa obtained approval for additional indication in Japan for adjuvant therapy for ALK-positive non-small cell lung cancer. We are very pleased that these in-house developed products can contribute to the treatment of more patients. In early-stage development, our in-house project RAY121 initiated a phase Ib basket trial targeting six autoimmune diseases, aiming for early value maximization. This basket trial approach outside the oncology field is a novel challenge with few precedents worldwide. We will continue to pursue innovation to deliver innovative new drugs to patients around the world," said Dr. Osamu Okuda, Chugai’s President and CEO.

Chugai reported increased revenue by 3.7% and operating profit by 25.3% year-on-year for the third quarter (nine months, Core-basis), mainly driven by strong overseas exports, and increase in other revenue.

Regarding revenue, domestic sales decreased by 22.7%. In the oncology field, although the growth of new product Phesgo was favorable, the overall decrease was 5.8% due to Avastin biosimilars and other impacts. In the specialty field, sales decreased by 36.4%, mainly due to continued impact of the completion of Ronapreve supply to the government in the previous year, while our new product Vabysmo grew and PiaSky was launched positively, and our mainstay product Actemra performed well. Overseas, Hemlibra’s exports to Roche increased greatly by 47.9%, leading to the increase by 33.8% in total overseas sales. Our mainstay product Alecensa also performed well, and Enspryng almost doubled its sales compared to the previous year. Other revenue increased by 23.8%, driven by the increase in Hemlibra related income including royalties, and one-time income.

Cost to sales ratio improved by 10.6 percentage points year-on-year to 32.5%, mainly due to a change in the product mix. Research and development expenses increased by 5.1% mainly due to investments into drug discovery and early development, and increases associated with the progress of development projects. Selling, general and administration expenses increased by 1.5% mainly due to foreign exchange rate fluctuations and an increase in the enterprise tax (pro forma standard taxation). Other operating income (expense) was ¥2.4 billion in income, including the recognition of income from disposal of product rights. As a result, Core operating profit totaled ¥426.6 billion (+25.3%).

Chugai also made good progress in research and development, in both early and late stages of developments.

For in-house products, Alecensa has been granted additional indication in Japan and Taiwan for adjuvant treatment of ALK-positive non-small cell lung cancer (NSCLC). Additionally, PiaSky, an anti-complement (C5) recycling antibody, has been approved in Europe for the treatment of paroxysmal nocturnal hemoglobinuria (PNH). It is the first monthly (every four weeks) subcutaneous treatment for PNH in Europe. Furthermore, NEMLUVIO, developed by Galderma outside of Japan, has been approved under priority review in the U.S. as the treatment of adults with prurigo nodularis. In early development, RAY121, an anti-complement C1s recycling antibody, has initiated a phase Ib clinical study as a basket study in six autoimmune diseases. Moreover, BRY10 has initiated a phase I clinical study for chronic diseases and has been added to the pipeline.

For the products in-licensed from Roche, delandistrogene moxeparvovec, a gene therapy product (development code: SRP-9001, overseas product name: Elevidys) has been filed for Duchenne muscular dystrophy. Additionally, Vabysmo has been filed for an additional indication for angioid streaks associated with neovascularization. Evrysdi has been approved for an additional indication for pre-symptomatic spinal muscular atrophy (SMA) and an additional dosage for SMA infants under 2 months of age. Furthermore, divarasib, the KRAS G12C inhibitor, has initiated a phase III clinical study for second-line treatment of NSCLC. In addition, Chugai has in-licensed the PI3K inhibitor inavolisib for PIK3CA-mutated breast cancer and the anti-TL1A therapy RG6631 for refractory diseases such as ulcerative colitis and Crohn’s disease.

Chugai raised forecasts (Core-basis) for FY2024 following the strong nine-month results. Regarding domestic sales, the forecasted sales amount reflects the progress and revised assumptions for products including Phesgo, Polivy, Vabysmo, and Perjeta. For overseas sales, mainly Hemlibra and Actemra exports to Roche have been forecasted to be higher than the original forecast. For other revenue, the forecasts for items including one-time income and royalties have also been updated. As a result, revenue has been raised to ¥1,150.0 billion, an increase of ¥80.0 billion from the initial forecast. Operating profit forecast has been revised to ¥540.0 billion, up ¥80.0 billion from the initial forecast, taking into account a lower cost to sales ratio due to a change in the product mix from the initial assumption, and increase in some expenses.

Reflecting the significant changes in the business environment, year-end dividend forecast has been revised to undecided. The year-end dividends will be decided after the fiscal year end based on basic profit distribution principles*.
*Regarding income distribution, taking into account the strategic funding needs and earning prospects, Chugai aims for a consolidated dividend payout ratio of 45% on average in comparison with Core EPS to provide a stable allocation of profit to all shareholders.

[2024 third quarter results]

Billion JPY 2024
Jan – Sep 2023
Jan – Sep % change
Core results
 Revenue 868.5 837.6 +3.7%
  Sales 750.3 742.1 +1.1%
  Other revenue 118.2 95.5 +23.8%
 Operating profit 426.6 340.5 +25.3%
 Net income 301.3 250.3 +20.4%
IFRS results
 Revenue 868.5 837.6 +3.7%
 Operating profit 418.6 317.6 +31.8%
 Net income 295.8 234.3 +26.2%
[Sales breakdown]

Billion JPY 2024
Jan – Sep 2023
Jan – Sep % change
Sales 750.3 742.1 +1.1%
 Domestic sales 331.7 429.2 -22.7%
  Oncology 180.3 191.4 -5.8%
  Specialty 151.3 237.9 -36.4%
 Overseas sales 418.7 312.9 +33.8%
[Oncology field (Domestic) Top5-selling medicines]

Billion JPY 2024
Jan – Sep 2023
Jan – Sep % change
 Tecentriq 47.4 47.9 -1.0%
 Avastin 25.6 38.2 -33.0%
 Polivy 24.5 25.5 -3.9%
 Alecensa 22.4 22.0 +1.8%
 Perjeta 15.7 24.6 -36.2%
[Specialty field (Domestic) Top5-selling medicines plus Ronapreve]

Billion JPY 2024
Jan – Sep 2023
Jan – Sep % change
 Hemlibra 41.5 40.5 +2.5%
 Actemra 34.8 32.2 +8.1%
 Enspryng 17.8 16.9 +5.3%
 Vabysmo 14.7 10.8 +36.1%
 Evrysdi 11.3 10.3 +9.7%
 Ronapreve* - 81.2 -100.0%
*Ronapreve has not been listed in the National Health Insurance (NHI) price list.

[Forecasts for 2024 Jan-Dec]

Billion JPY Revised forecast
on Oct 25 Original forecast
on Feb 1 Growth vs
original forecast Growth vs
2023 actual
Core-basis
Revenue 1,150.0 1,070.0 +7.5% +38.6, +3.5%
 Sales 986.0 922.0 +6.9% +11.5, +1.2%
 Other revenue 164.0 148.0 +10.8% +27.1, +19.8%
Operating profit 540.0 460.0 +17.4% +89.3, +19.8%

About Core results

Chugai discloses its results on a Core basis from 2013 in conjunction with its decision to apply IFRS. Core results are the results after adjusting non-Core items to IFRS results. Chugai’s recognition of non-recurring items may differ from that of Roche due to the difference in the scale of operations, the scope of business and other factors. Core results are used by Chugai as an internal performance indicator, for explaining the underlying business performance both internally and externally, and as the basis for payment-by-results such as a return to shareholders.

Trademarks used or mentioned in this release are protected by law.